MHRA Unveils AI Sandbox to Transform Medicines Development & Strengthen Drug Safety
Advertisement
Up to five AI-based approaches will be selected during the first phase, with collaboration between regulators, academic institutions and industry partners expected to begin in summer 2026.
The Medicines and Healthcare products Regulatory Agency (MHRA) has announced the launch of a first-of-its-kind AI sandbox that will enable developers, researchers and regulators to evaluate artificial intelligence applications for medicines development.
The initiative is intended to strengthen drug safety assessments, support faster development of new treatments, and explore alternatives to traditional testing methods, including animal studies.
Health Innovation Minister Preet Gill said, “By giving innovators a safe space to test these tools alongside regulators, we can build the evidence base needed to get safer, more effective treatments to patients faster. That means fewer adverse reactions, less reliance on animal testing, and a smarter, more efficient medicines development process.”
Supported by funding from the UK Government’s Regulatory Innovation Office, the AI sandbox will explore whether advanced computational models can improve predictions related to drug absorption, metabolism, safety risks and potential side effects.
Researchers will also examine how clinical data can be used more effectively to understand how medicines perform across diverse populations, including children, older adults and communities that have historically been underrepresented in clinical research.
Lord Vallance, Minister for Science, Innovation, Research and Nuclear, said, “By leveraging our strengths in life sciences, AI and pro-innovation regulation, this sandbox will help make the UK one of the best places in the world to develop the next generation of medicines safely.”
The MHRA plans to use evidence generated through the programme to assess the reliability of AI-driven approaches and determine whether they can support future regulatory decision-making.
By creating clearer expectations around the use of AI in drug development, the agency aims to provide innovators with greater confidence to invest in new technologies and bring therapies to market more efficiently.
The sandbox is also aligned with broader UK ambitions to modernise medicines development through advanced modelling, synthetic data and alternative research methods that could reduce dependence on animal testing.
Up to five AI-based approaches will be selected during the first phase, with collaboration between regulators, academic institutions and industry partners expected to begin in summer 2026.
Stay tuned for more such updates on Digital Health News
